The pharmaceutical industry at risk: How excessive government regulation stifles innovation

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 2, 2007, Pages 131-132

  Epstein, R A ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; GENERIC DRUG;

DRUG COST; DRUG INDUSTRY; DRUG LABELING; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HUMAN; LAW SUIT; PATENT; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

DRUG INDUSTRY; GOVERNMENT REGULATION; HUMANS; ORGANIZATIONAL INNOVATION; RISK ASSESSMENT; RISK SHARING, FINANCIAL;

EID: 34447572759     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100257     Document Type: Review

References (0)